CD307B抗体,Mouse Monoclonal CD307B Antibody
  • CD307B抗体,Mouse Monoclonal CD307B Antibody
  • CD307B抗体,Mouse Monoclonal CD307B Antibody
  • CD307B抗体,Mouse Monoclonal CD307B Antibody

CD307B抗体—艾普蒂

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 上海
更新日期 2025-05-15
QQ交谈 微信洽谈

产品详情

中文名称:CD307B抗体英文名称:Mouse Monoclonal CD307B Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 1171 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Mouse
偶联物: 靶点: CD307B
2025-05-15 CD307B抗体 Mouse Monoclonal CD307B Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 1171 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB咨询技术 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC咨询技术 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM1/200 - 1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesFCRL2; FCRH2; IFGP4; IRTA4; SPAP1; SPAP1A; SPAP1B; SPAP1C
Entrez GeneID79368
clone7B12A3
WB Predicted band size55.5kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD307B (AA: extra 20-253) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    


  •  

     

       Flow cytometric analysis of HL-60 cells using CD307B mouse mAb (green) and negative control (red).    


           

参考文献

以下是假设存在的关于CD307B抗体的文献示例(非真实文献,仅作格式参考):

---

1. **文献名称**:*CD307B as a novel regulator of B-cell signaling in autoimmune diseases*

**作者**:Zhang et al., 2020

**摘要**:研究揭示了CD307B(Fc受体家族成员)在B细胞活化中的调控作用,发现其通过抑制BCR信号通路减轻小鼠模型中的类风湿性关节炎症状,提示其作为自身免疫疾病治疗靶点的潜力。

2. **文献名称**:*Structural characterization of CD307B and its interaction with antigens*

**作者**:Smith et al., 2018

**摘要**:通过X射线晶体学解析CD307B胞外域结构,发现其与IgG的结合模式不同于其他Fc受体,并提出其可能参与抗原呈递或免疫复合物清除的新机制。

3. **文献名称**:*CD307B expression correlates with poor prognosis in B-cell lymphoma*

**作者**:Tanaka et al., 2019

**摘要**:临床分析显示,CD307B在弥漫大B细胞淋巴瘤中高表达,且与化疗耐药性相关,提示其可作为预后标志物或单抗药物开发靶点。

4. **文献名称**:*CD307B deficiency enhances anti-tumor immunity in murine models*

**作者**:Wang et al., 2021

**摘要**:CD307B敲除小鼠的肿瘤微环境中T细胞浸润增加,肿瘤生长受抑制,表明靶向CD307B可能通过调节免疫抑制微环境增强癌症免疫治疗效果。

---

注:以上内容为模拟虚构,实际文献需通过PubMed、Google Scholar等平台检索。

       

背景信息

CD307B, also known as Fc receptor-like protein 5 (FCRL5), is a member of the Fc receptor-like (FCRL) family, which shares structural homology with classical Fc receptors but lacks binding affinity for immunoglobulins. Expressed predominantly on B cells, particularly memory B cells and plasma cells, CD307B is implicated in regulating B-cell activation, differentiation, and immune responses. Its extracellular region contains immunoglobulin-like domains, while its cytoplasmic tail features immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs), suggesting dual regulatory roles in signaling pathways.

CD307B has garnered attention for its potential involvement in autoimmune diseases, infections, and B-cell malignancies. Studies highlight its upregulated expression in conditions like rheumatoid arthritis, systemic lupus erythematosus (SLE), and chronic lymphocytic leukemia (CLL), where it may modulate pathogenic antibody production or cell survival. Additionally, CD307B serves as a marker for atypical memory B cells in malaria and HIV, linking it to chronic antigen exposure.

Therapeutic interest in CD307B arises from its restricted expression on abnormal B-cell subsets, making it a candidate for targeted therapies. Antibodies against CD307B are being explored for diagnostic applications, drug delivery, and engineered CAR-T cell therapies. However, its precise ligand interactions and signaling mechanisms remain under investigation, necessitating further research to clarify its role in immune regulation and disease pathogenesis.

       
关键字: CD307B抗体;CD307B;CD307B Antibody;

公司简介

是一家科研、开发、生产和销售为一体的科技型企业,
成立日期 2024-07-02 (2年) 注册资本 20万人民币
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 抗体,蛋白组学,细胞生物学 经营模式 贸易,工厂,试剂,定制,服务
  • 上海切尔齐生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:20万人民币
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:重组蛋白、抗体、生物试剂
  • 公司地址:青浦区
询盘

CD307B抗体—艾普蒂相关厂家报价

产品名称 价格   公司名称 报价日期
询价
上海华盈生物医药科技有限公司
2026-02-15
询价
VIP4年
维百奥(北京)生物科技有限公司
2025-12-29
¥1800
VIP2年
费雪(杭州)医学研究有限公司
2026-01-05
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.